Neoplasms, Plasma Cell: all 2,314 studies

Page 4 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.

• Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple MyelomaTerminatedNCT03782064Phase 2Results posted
• LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple MyelomaCompletedNCT03773107Phase 1/2Results posted
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedNCT03770260Phase 1Results posted
• Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)CompletedNCT03748953Phase 3Results posted
• Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT03702725Phase 1Results posted
• Tinostamustine Conditioning and Autologous Stem CellTerminatedNCT03687125Phase 1/2Results posted
• First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal AntibodyCompletedNCT03665155Phase 1/2Results posted
• PK of Melphalan During Treatment With Melflufen and Dexamethasone in Patients With RRMM and Impaired Renal FunctionTerminatedNCT03639610Phase 2Results posted
• Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)TerminatedNCT03634800Phase 2Results posted
• A Safety Study of SEA-BCMA in Patients With Multiple MyelomaTerminatedNCT03582033Phase 1Results posted
• A Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT03567616Phase 2Results posted
• To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT03544281Phase 1/2Results posted
• A Study of Carfilzomib Plus Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma at US Community Oncology CentersTerminatedNCT03512353Phase 2Results posted
• Multiple Myeloma (MM) Profile in Brazil: A Retrospective Observational AnalysisCompletedNCT03506386Results posted
• Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted
• Short Course Daratumumab in Patients With Multiple MyelomaCompletedNCT03490344Phase 2Results posted
• Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMMTerminatedNCT03481556Phase 1/2Results posted
• Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' ExpressionCompletedNCT03480360Phase 3Results posted
• Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients With Multiple Myeloma Resistant to ChemotherapyTerminatedNCT03457142Phase 2Results posted
• Efficacy of Daratumumab in Patients With Relapsed/Refractory Myeloma With Renal ImpairmentCompletedNCT03450057Phase 2Results posted
• Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance TreatmentTerminatedNCT03440411Phase 3Results posted
• A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)CompletedNCT03439293Phase 2Results posted
• A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)CompletedNCT03439280Phase 1/2Results posted
• A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and DexamethasoneCompletedNCT03433001Results posted
• Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell TransplantationCompletedNCT03417284Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based TherapyCompletedNCT03416374Phase 4Results posted
• A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment RegimensCompletedNCT03412565Phase 2Results posted
• Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on LenalidomideTerminatedNCT03411031Phase 2Results posted
• Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple MyelomaCompletedNCT03398200Phase 2Results posted
• Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple MyelomaCompletedNCT03361748Phase 2Results posted
• A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03357952Phase 2/3Results posted
• Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)TerminatedNCT03340883Phase 1/2Results posted
• Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple MyelomaCompletedNCT03338972Phase 1Results posted
• Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03333746Phase 2Results posted
• A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results posted
• Allogeneic Stem Cell Transplantation for Multiple Myeloma and MyelofibrosisTerminatedNCT03303950Phase 2Results posted
• P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)TerminatedNCT03288493Phase 1/2Results posted
• APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple MyelomaTerminatedNCT03287804Phase 1/2Results posted
• A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03277105Phase 3Results posted
• PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple MyelomaCompletedNCT03269136Phase 1Results posted
• Comparison of F-18 FDG and C-11 Acetate PET in Multiple MyelomaCompletedNCT03262389Phase 2Results posted
• Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT03256045Phase 2Results posted
• Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple MyelomaCompletedNCT03224507Phase 2Results posted
• MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple MyelomaTerminatedNCT03218163Phase 2Results posted
• Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple MyelomaCompletedNCT03202628Phase 2Results posted
• Cabozantinib as a Targeted Strategy to Reverse Carfilzomib Resistance in Refractory Multiple MyelomaTerminatedNCT03201250Phase 1/2Results posted
• Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) PatientsCompletedNCT03194867Phase 1/2Results posted
• Clinical and Sociodemographic Characterization of Multiple Myeloma Participants With Symptomatic Relapse and/or Refractory Disease in Spain (CharisMMa Study)CompletedNCT03188536Results posted
• Bendamustine and Melphalan in MyelomaCompletedNCT03187223Phase 2Results posted
• A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple MyelomaCompletedNCT03170882Phase 2Results posted
• Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaTerminatedNCT03168438Phase 1Results posted
• Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.CompletedNCT03158688Phase 3Results posted
• A Study of Melphalan Flufenamide (Melflufen)-Dex or Pomalidomide-dex for RRMM Patients Refractory to LenalidomideTerminatedNCT03151811Phase 3Results posted
• High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell TransplantCompletedNCT03128359Phase 2Results posted
• Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideTerminatedNCT03117361Phase 2Results posted
• Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaCompletedNCT03110562Phase 3Results posted
• Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple MyelomaCompletedNCT03029234Phase 3Results posted
• Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT03012880Phase 2Results posted
• A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)CompletedNCT03000452Phase 2Results posted
• Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma PatientsCompletedNCT02990338Phase 3Results posted
• A Study of Melphalan Flufenamide (Melflufen) Plus Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02963493Phase 2Results posted
• Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple MyelomaCompletedNCT02958969Phase 4Results posted
• A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple MyelomaCompletedNCT02951819Phase 2Results posted
• Daratumumab in Treating Patients With Multiple MyelomaCompletedNCT02944565Phase 2Results posted
• Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma PatientsTerminatedNCT02943473Phase 2Results posted
• Study Testing Radium-223 Dichloride in Relapsed Multiple MyelomaTerminatedNCT02928029Phase 1/2Results posted
• A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin LymphomaCompletedNCT02919670Not applicableResults posted
• A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple MyelomaCompletedNCT02917941Phase 2Results posted
• Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)TerminatedNCT02906332Phase 2Results posted
• A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering MyelomaCompletedNCT02903381Phase 2Results posted
• Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple MyelomaCompletedNCT02902965Phase 2Results posted
• Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell TransplantCompletedNCT02880228Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple MyelomaCompletedNCT02874742Phase 2Results posted
• Oral ONC201 in Relapsed/Refractory Multiple MyelomaTerminatedNCT02863991Phase 1/2Results posted
• Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma PatientsCompletedNCT02843074Phase 2Results posted
• Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma PatientsCompletedNCT02812706Phase 1/2Results posted
• A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple MyelomaTerminatedNCT02807454Phase 2Results posted
• CART-19 Post-ASCT for Multiple MyelomaTerminatedNCT02794246Phase 2Results posted
• Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple MyelomaCompletedNCT02780609Phase 1/2Results posted
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Results posted
• ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaTerminatedNCT02757326Phase 1/2Results posted
• A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT02755597Phase 3Results posted
• Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple MyelomaTerminatedNCT02739594Phase 3Results posted
• Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)CompletedNCT02728102Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedNCT02726581Phase 3Results posted
• Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)CompletedNCT02722941Phase 2Results posted
• A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)TerminatedNCT02720510Phase 2Results posted
• Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)CompletedNCT02703779Phase 2Results posted
• Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell TransplantationTerminatedNCT02700841Phase 2Results posted
• A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaCompletedNCT02685826Phase 1/2Results posted
• Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationCompletedNCT02669615Phase 2Results posted
• SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaTerminatedNCT02661022Phase 1/2Results posted
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2Results posted
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)CompletedNCT02654132Phase 2Results posted
• Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02633059Phase 1/2Results posted
• Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCTTerminatedNCT02619812Phase 2Results posted
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedNCT02612779Phase 2Results posted
• High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple MyelomaCompletedNCT02597062Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)TerminatedNCT02579863Phase 3Results posted

← Neoplasms, Plasma Cell overview